Natus Medical, a provider of medical devices focused on the screening, diagnosis and treatment of central nervous and sensory system disorders, has entered into an agreement to acquire Micromed Holding SAS (“Micromed Group” or “Micromed”), a global provider of neurophysiology solutions. The transaction is expected to close in early 2023, subject to the receipt of regulatory approvals, according to a statement from Natus Medical.

The acquisition of Micromed will be the first transaction by Natus since being acquired by the ArchiMed Group (“ARCHIMED”) in July of this year. 

“We are pleased to make this first growth-oriented investment as an ARCHIMED portfolio company,” says Thomas J. Sullivan, Natus CEO, in a statement. “The breadth and depth of clinical expertise in Natus and Micromed will enable us to bring exciting innovation to our neuroscience customers and their patients around the globe,”  

Together, Natus and Micromed will provide customers with a portfolio of neurodiagnostic and neuromonitoring solutions. A Natus legacy of over 85 years of neurodiagnostic leadership including brands such as NeuroWorks/SleepWorks, Natus Quantum, Grass, Nicolet, Xltek, Embla, Dantec TECA and others will combine with the complete line of Micromed solutions including BRAIN QUICK/MYOQUICK, NEUROWERK, SleepRT and MOBERG.

The products will also enable a strong platform for new product development in electroencephalography (EEG), polysomnography (PSG), electromyography (EMG), and intensive care unit (ICU) monitoring through the integration of the best aspects of both product portfolios, including backward compatibility.

“Joining the forces of the Natus and Micromed teams with their collective knowledge and passion for neurodiagnostics and neurocritical care, will result in both a more comprehensive product offering and an unrivaled global service and support structure for the benefit of our customers,” says Austin Noll, Natus president and leader of Natus Neuro, in a statement. “The management of our new Natus neuro team will work closely with Micromed management to build upon the Micromed momentum in the European epilepsy market and the emerging presence of Moberg in the ICU.”

ID 94512900 © Ronstik |